Two new CareLink™ reports for MiniMed™ 670G system users

In diabetes management, as in so many aspects of life, knowledge (and understanding) is power. Fortunately, CareLink™ software gives you valuable information to help you better understand your diabetes. With comprehensive, actionable insights based on your pump and CGM information, you and your healthcare team have what you need to collaborate how best to optimize your diabetes management. 

The revolutionary new MiniMed™ 670G system reveals important information about your individual diabetes. That’s why we now have two brand new CareLink™ reports that allow you to have a more productive conversation with your healthcare professional. These reports will help you spend less time looking at problems and more time evaluating solutions to maximize the impact of SmartGuard™ HCL technology.

Assessment & Progress report

This new report lets you view information over time, celebrate daily diabetes wins, and identify opportunities to talk with your healthcare team. You can easily see the amount of time you’re spending between 70-180 mg/dL, which is called Time in Range. Rather than focusing on averages, Time in Range gives you a fuller picture of how much of your day is spent without highs and lows so you can spend more time living your life. 

You can learn more about this report by clicking here.

Weekly Review report

This second report shows how much time you've spent in Manual Mode versus Auto Mode. The MiniMed™ 670G system with SmartGuard™ HCL technology has safety mechanisms in place that may exit you from Auto Mode in certain circumstances. In this report, the gray shading helps focus attention on when you were exited from Auto Mode and how much time was spent in Manual Mode. This helps you to evaluate the reasons for exits and identify ways to increase time in Auto Mode. 

You can learn more about this report by clicking here. 

We’d love to hear from you on these new reports. And maybe your thoughts will be used for future updates. 

1. CareLink™ reports are designed to provide better information and not just data.  What are your favorite parts of the new CareLink™ reports? 

2. CareLink™ software is a tool to help you better understand your diabetes. How do you use the information on CareLink™ reports? 

3. Every day is a new opportunity to celebrate what’s going well. What does the information in the CareLink™ reports mean to you? How does it make you feel? 

If it’s been a while since you’ve logged in, visit the CareLink™ website today. Need help logging in? Visit our support section. There is so much you can learn about day-to-day life with diabetes by looking at your pump and glucose data in a more holistic way. Enjoy the new reports and let us know if you have any questions!  

IMPORTANT SAFETY INFORMATION
 

CareLink^® Therapy Management Software for Diabetes is intended to be used together with advice from a healthcare professional familiar with the diagnosis and treatment of diabetes. Do not make any changes to treatment without talking to a healthcare professional first. For more information, please visit www.medtronicdiabetes.com/about/safety.html.

The Medtronic MiniMed 670G system requires a prescription and is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.

The Guardian Sensor (3) is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).

Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Do not use the serter on products other than the Enlite sensor or Guardian Sensor (3). Medtronic cannot guarantee the safety or efficacy of this product if used with other products. The reservoir is contraindicated for the infusion of blood or blood products. Infusion sets are indicated for subcutaneous use only and not for intravenous (IV) infusion or the infusion of blood or blood products. Insulin pump therapy is not recommended for those who are unwilling to perform at least four blood glucose tests per day. As insulin pumps use rapid acting insulin only, BG testing is required to help identify rapid glycemic deterioration due to insulin infusion occlusion, infusion site problems, insulin stability issues, user error, or a combination of these. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional.

The safety of the 670G system has not been studied in people with impaired kidney function. Please let your healthcare professional know if you have kidney disease so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks. The safety of the 670G system has not been studied in pregnant women, people with type 2 diabetes, or in people using other anti-hyperglycemic therapies apart from insulin. Please let your healthcare professional know if any of these conditions apply to you so you and your healthcare professional can determine if the potential benefits of using the system outweigh the risks.

For complete safety information, please consult the appropriate User Guide.